Financial Data and Key Metrics Changes - The company reported an 11% revenue increase year-over-year, marking the seventh consecutive quarter of double-digit growth [7][14] - Adjusted diluted earnings per share increased to $0.90 from $0.73 in the prior year [30] - Adjusted operating income rose to $64 million, with an operating income margin of 20%, up from 16% in the previous year [29] Business Segment Data and Key Metrics Changes - Cardiopulmonary segment revenue was $172 million, a 15% increase compared to Q3 2023, driven by over 20% growth in heart-lung machine revenue [15] - Epilepsy segment revenue increased by 9%, with U.S. epilepsy revenue growing 10% year-over-year [17] Market Data and Key Metrics Changes - U.S. revenue grew by 15%, while Europe and the rest of the world saw a 9% increase [8] - The company gained market share in the oxygenator market, increasing from the low 30s to the mid-30s percentage [9] Company Strategy and Development Direction - The company aims to maximize core businesses in epilepsy and cardiopulmonary while exploring growth in difficult-to-treat depression and obstructive sleep apnea [44] - A focus on innovation is evident, with ongoing development in cardiopulmonary and epilepsy pipelines, as well as new products in the oxygenator segment [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining above-market growth, supported by healthy market conditions and successful product launches [10][12] - The company anticipates a slowdown in revenue growth in Q4 due to strong performance comparisons from the previous year [48] Other Important Information - The company is increasing its 2024 full-year guidance, expecting revenue growth between 8.5% and 9.5% on a constant currency basis [33] - Adjusted free cash flow is projected to be between $110 million and $130 million, reflecting a 25% increase at midpoint compared to the prior year [36] Q&A Session Summary Question: Strategy on portfolio management and R&D deployment - Management highlighted a focus on maximizing core businesses and reinvesting in R&D for sustainable innovation [42][44] Question: Assumptions for Q4 revenue growth - The anticipated slowdown is attributed to strong performance in Q4 2023, not a decline in fundamentals [48][49] Question: 2025 growth expectations - Management refrained from providing specific guidance for 2025 but indicated potential for high single-digit growth if all growth levers perform positively [50][52] Question: Oxygenator market outlook - The company noted ongoing supply constraints in the oxygenator market, driven by increased procedure growth and capacity limitations among competitors [55][62] Question: Innovation timelines for new products - Management indicated that many innovation programs are in mid-to-late development stages, with some expected to progress in 2025 [66] Question: Impact of potential reimbursement changes for epilepsy - Management expressed optimism that changes in Medicare reimbursement could lead to increased utilization of VNS therapy for drug-resistant epilepsy [84][86]

| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova Third-Quarter 2024 | | | | | | Earnings Update | | | | | | October 30, 2024 | | | | | Safe Harbor 2 Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements inc ...

LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 26.76%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.93, delivering a surprise of 17.72%. Over the last four quarters, ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2024 Results London, October 30, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights (1) • Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (AC ...

If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65. The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Ro ...

Financial Performance - Net revenue increased by 9.6% on a constant-currency basis to $318.6 million[1,4] - Excluding the ACS segment wind down, net revenue increased 10.8% on a constant-currency basis[94,73] - The company is targeting $95 - $115 million of adjusted free cash flow for full-year 2024[11] - LTM adjusted free cash flow was $139.9 million with an LTM adjusted free cash flow conversion ratio of 79%[11] Segment Performance - Cardiopulmonary revenue increased 14.5% to $173.7 million, driven by strong demand for consumables and Essenz sales[80,81] - Neuromodulation revenue increased 7.8% to $142.9 million, with growth across all regions[83,84] - United States Cardiopulmonary revenue increased 29.7% to $64.9 million[77] - United States Neuromodulation revenue increased 7.3% to $111.7 million[77] Guidance - The company is raising full-year guidance for net revenue growth to 7-8% and net revenue growth, excluding ACS, to 9-10%[31] - The company is raising full-year guidance for adjusted diluted EPS to $3.10 - $3.20[31]

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this medical technology company would post earnings of $0.45 per share when it actually produced earnings of $0.73, delivering a surprise of 62.22%. Over the last four quarters, ...

EXHIBIT 99.1 London, July 31, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. • Announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study on June 6, 2024. Following additional in-depth analyses of the data, intends to pursue U.S. Centers for Medicare and Medicaid Services coverage for VNS Therapy™ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...